clenbuterol has been researched along with Tremor in 11 studies
Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.
Tremor: Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For clenbuterol, the same was also observed in comparison with placebo, while for procaterol this was true only for FEV1 and FEF25-75, while no difference resulted from FVC and PEF." | 6.66 | Oral clenbuterol and procaterol. A double-blind comparison of bronchodilator effects in children with chronic asthma. ( Boner, AL; Castellani, C; Schiassi, M; Sette, L, 1987) |
| " 10 micrograms of clenbuterol revealed no significant differences when compared to placebo, whereas the 20 micrograms dosage as usually administered in clinical routine demonstrated significant--but only slight--differences to placebo-baseline." | 6.66 | [Novel quantitative assessment of the tremorogenic effects of the beta 2-mimetics clenbuterol and salbutamol after oral administration]. ( Schaffler, K; Schuster, D, 1985) |
| "Clenbuterol is a long acting beta2-adrenergic agonist used in the treatment of pulmonary disorders." | 5.31 | Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels. ( Freyberg, CL; Hoffman, RJ; Hoffman, RS; Nelson, LS; Poppenga, RH, 2001) |
| "5 mg/kg it increased head-twitches and tremors induced by 1-5-hydroxytryptophan (4 mg/kg) and decreased the number of bites of a food pellet by mice which had been maintained on a water only diet for 24-27 h ('Tantale' test)." | 3.67 | Comparison of clenbuterol enantiomers using four psychopharmacological tests sensitive to beta-agonists. ( Brochet, D; Martin, P; Puech, AJ; Simon, P; Soubrié, P, 1985) |
| "The effects of two beta 2-adrenoceptor agonists with different lipophilicities were studied on tremor induced by L-5-hydroxytryptophan (L-5-HTP) in pargyline- and carbidopa-pretreated rats." | 3.67 | Central beta-adrenoceptors can modulate 5-hydroxytryptamine-induced tremor in rats. ( Hallberg, H, 1986) |
| " with clenbuterol (as Ventipulmin Syrup), beginning with the lowest dosage of 0." | 2.67 | Clinical efficacy and safety of clenbuterol HCl when administered to effect in horses with chronic obstructive pulmonary disease (COPD). ( Aviad, AD; Erichsen, DF; Kennedy, TJ; Schultz, RH, 1994) |
| "For clenbuterol, the same was also observed in comparison with placebo, while for procaterol this was true only for FEV1 and FEF25-75, while no difference resulted from FVC and PEF." | 2.66 | Oral clenbuterol and procaterol. A double-blind comparison of bronchodilator effects in children with chronic asthma. ( Boner, AL; Castellani, C; Schiassi, M; Sette, L, 1987) |
| " 10 micrograms of clenbuterol revealed no significant differences when compared to placebo, whereas the 20 micrograms dosage as usually administered in clinical routine demonstrated significant--but only slight--differences to placebo-baseline." | 2.66 | [Novel quantitative assessment of the tremorogenic effects of the beta 2-mimetics clenbuterol and salbutamol after oral administration]. ( Schaffler, K; Schuster, D, 1985) |
| "Clenbuterol is an oral β2-agonist with anabolic and lipolytic effects that is misused as a performance and image enhancing drug." | 1.56 | Clenbuterol: a new toxic substance in paediatrics. ( Logan, S; McKie, A; Pollock, L; Tester, AA, 2020) |
| "Clenbuterol is a long-acting β-adrenergic agonist that is not Food and Drug Administration-approved for use in the United States, but may be obtained without a prescription from various unregulated sellers." | 1.51 | Toxicity From Unintentional Pediatric Ingestion of a Performance-Enhancing Drug: A Case Report With Review of Clenbuterol Toxicity and Treatment. ( Bonney, CF; Hatten, B; Wang, GS, 2019) |
| "Clenbuterol is a long acting beta2-adrenergic agonist used in the treatment of pulmonary disorders." | 1.31 | Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels. ( Freyberg, CL; Hoffman, RJ; Hoffman, RS; Nelson, LS; Poppenga, RH, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (45.45) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bonney, CF | 1 |
| Hatten, B | 1 |
| Wang, GS | 1 |
| Tester, AA | 1 |
| Logan, S | 1 |
| Pollock, L | 1 |
| McKie, A | 1 |
| Nawrocka, I | 1 |
| Kowalczys, MH | 1 |
| Abramczyk, P | 1 |
| Erichsen, DF | 1 |
| Aviad, AD | 1 |
| Schultz, RH | 1 |
| Kennedy, TJ | 1 |
| Jensen, K | 1 |
| Hoffman, RJ | 1 |
| Hoffman, RS | 1 |
| Freyberg, CL | 1 |
| Poppenga, RH | 1 |
| Nelson, LS | 1 |
| Martin, P | 2 |
| Puech, AJ | 1 |
| Brochet, D | 2 |
| Soubrié, P | 2 |
| Simon, P | 2 |
| Hallberg, H | 1 |
| Boner, AL | 1 |
| Sette, L | 1 |
| Castellani, C | 1 |
| Schiassi, M | 1 |
| Schaffler, K | 1 |
| Schuster, D | 1 |
3 trials available for clenbuterol and Tremor
| Article | Year |
|---|---|
Clinical efficacy and safety of clenbuterol HCl when administered to effect in horses with chronic obstructive pulmonary disease (COPD).
Topics: Animals; Bronchodilator Agents; Clenbuterol; Dose-Response Relationship, Drug; Female; Horse Disease | 1994 |
Oral clenbuterol and procaterol. A double-blind comparison of bronchodilator effects in children with chronic asthma.
Topics: Administration, Oral; Asthma; Bronchodilator Agents; Child; Clenbuterol; Double-Blind Method; Ethano | 1987 |
[Novel quantitative assessment of the tremorogenic effects of the beta 2-mimetics clenbuterol and salbutamol after oral administration].
Topics: Administration, Oral; Adult; Albuterol; Blood Pressure; Clenbuterol; Clinical Trials as Topic; Dose- | 1985 |
8 other studies available for clenbuterol and Tremor
| Article | Year |
|---|---|
Toxicity From Unintentional Pediatric Ingestion of a Performance-Enhancing Drug: A Case Report With Review of Clenbuterol Toxicity and Treatment.
Topics: Adrenergic beta-Agonists; Child, Preschool; Clenbuterol; Eating; Female; Humans; Hypotension; Intens | 2019 |
Clenbuterol: a new toxic substance in paediatrics.
Topics: Acidosis; Adolescent; Adrenergic beta-Agonists; Chest Pain; Clenbuterol; Diagnosis, Differential; El | 2020 |
Acute clenbuterol overdose manifestations in a suicide attempt--a case report.
Topics: Adult; Clenbuterol; Drug Overdose; Humans; Hypokalemia; Male; Suicide, Attempted; Tachycardia, Sinus | 2015 |
[Tremor--in cattle and human beings--when exposed to growth promoters].
Topics: Adrenergic beta-Agonists; Animals; Cattle; Cattle Diseases; Clenbuterol; Food Contamination; Foodbor | 2000 |
Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels.
Topics: Adrenergic beta-Agonists; Adult; Clenbuterol; Electrocardiography; Enzyme-Linked Immunosorbent Assay | 2001 |
Comparison of clenbuterol enantiomers using four psychopharmacological tests sensitive to beta-agonists.
Topics: 5-Hydroxytryptophan; Adrenergic beta-Agonists; Animals; Apomorphine; Behavior, Animal; Body Temperat | 1985 |
Central beta-adrenoceptors can modulate 5-hydroxytryptamine-induced tremor in rats.
Topics: 5-Hydroxytryptophan; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Clenbuterol; Ma | 1986 |
Effects of triiodothyronine on the 5-hydroxytryptophan-induced head twitch and its potentiation by antidepressants in mice.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Clenbuterol; Dose-Response Relationship, Drug; | 1985 |